Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences
Release Date: 06/29/2026
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki TRANSCRIPT
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outline
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health TRANSCRIPT
Empowered Patient Podcast
Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...
info_outline
Integrated Continuous Data-Driven Care for Severe Mental Illness with Sonia Garcia Amae Health
Empowered Patient Podcast
Sonia Garcia, Co-Founder and Chief Growth Officer at Amae Health, an integrated care company specializing in the treatment of severe mental illness that operates community-oriented clinics to deliver comprehensive psychiatry-led care. They provide continuity of care across multiple acuity levels, recognizing these conditions require long-term management. Amae is also advancing psychiatric care through research and partnerships by deploying wearables for health monitoring and investigating biomarkers and pharmacogenomics to improve treatment outcomes. Sonia explains, "Amae Health is an...
info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO TRANSCRIPT
Empowered Patient Podcast
Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...
info_outline
Expanding Advanced Lung Transplant Assessment and Utilization with Sarah Lowe XVIVO
Empowered Patient Podcast
Sarah Lowe, Global Clinical Operations Director at XVIVO, develops technologies to preserve, assess, and transport organs for transplantation. With advanced assessment of donor lungs, the mission is to evaluate marginal organs better to address the critical challenge that only 2 out of 10 available lungs are currently accepted for transplant. With their first in-house ex vivo lung perfusion program, the goal is to increase organ utilization and expand access to transplants. Sarah explains, "At XVIVO, our vision really is that nobody should die waiting for a new organ. As a company, we develop...
info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI TRANSCRIPT
Empowered Patient Podcast
Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...
info_outline
Platform Targets Root Causes of Disease to Drive Drug Discovery with Vin Singh Bullfrog AI
Empowered Patient Podcast
Vin Singh, Founder, Chairman, and CEO of Bullfrog AI, is applying proprietary AI technology to drug development, with a focus on drug target discovery and phase three clinical trials. The company's platform is derived from the Johns Hopkins University Applied Physics Lab and is designed to pinpoint drug targets, identify the root causes of disease, and match patients to appropriate treatments based on genetic profiles. Bullfrog AI aims to reduce clinical trial timelines, improve success rates, identify more accurate biomarkers, and improve patient outcomes. Vin explains, "We are in the AI...
info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS TRANSCRIPT
Empowered Patient Podcast
Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...
info_outline
Addressing Social Drivers of Health to Improve Patient Outcomes with Dr. Greg Carroll ClinNEXUS
Empowered Patient Podcast
Dr. Greg Carroll, emergency physician and Co-Founder and CEO of ClinNEXUS, a data-first healthcare company addressing social drivers of health in underserved communities by breaking down data silos. Integrating clinical information with social, behavioral, and environmental factors and using AI to augment human care coordinators enables them to identify patient needs proactively and provide personalized support. The model emphasizes building trust through in-person engagement while leveraging digital tools to enhance the care manager's ability to process complex data and deliver...
info_outlineDr. Matthew Goldberg, Senior Vice President for Medical at Castle Biosciences, discusses the uncertainty clinicians face when determining treatments for skin cancer due to the limitations of traditional pathology reports. Castle's gene expression profile tests were developed to improve the accuracy of risk stratification for patients with cutaneous melanoma and high-risk cutaneous squamous cell carcinoma. These tests provide prognostic information by analyzing the tumor's RNA, offering more granular and accurate risk assessment and informing about the intensity of follow-up and long-term risk management strategies.
Matthew explains, "So this is an important topic for dermatologists who are really on the front lines of skin cancer diagnosis and management for patients who are confronting skin cancer today. I'm a board-certified dermatologist and dermatopathologist by training. And to me, I think that the core uncertainty is centered around some of the known limitations around the prognostic accuracy of pathology. That's kind of worth unpacking here, but I think what it comes down to is that dermatologists are involved in identifying concerning skin lesions, identifying and, through biopsy, taking a skin sample, and finding skin cancers."
"Dermatopathologists are the collaborative colleagues who interpret the skin biopsy samples and return the pathological diagnoses to the dermatologist. For the treating clinician, the key task is to understand the implications of the types of skin cancers identified in this process to determine the most appropriate, risk-aligned downstream management for patients with these skin cancers."
"So Castle Biosciences has developed a range of tests that are really focused on impactful skin cancers that are some of the biggest challenges for dermatologists and the patients that we serve in the clinic, specifically around cutaneous melanoma with the DecisionDx-Melanoma gene expression profile test and also high-risk cutaneous squamous cell carcinomas with the DecisionDx-SCC test."
#CastleBiosciences #SkinCancer #CancerCare #HealthcareInnovation #Dermatology #MolecularDiagnostics #PrecisionMedicine #RiskStratification #ClinicalDecisionMaking #DigitalPathology #Oncology #Melanoma #SquamousCellCarcinoma #GeneExpression #SharedDecisionMaking
